 |
What's at the Top of the Esophageal Diseases Agenda? Issues to Watch For! CME/CE David A. Peura, MD, Chair; William D. Chey, MD; Joel E. Richter, MD; Nicholas J. Shaheen, MD, MPH; Michael F. Vaezi, MD, PhD; Roy K. H. Wong, MD Author Information and Disclosures Release Date: January 7, 2008; Valid for credit through January 7, 2009 | Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians;
Nurses - 2.0 ANCC contact hours;
Pharmacists - 2.0 ACPE continuing education credits for pharmacists (0.2 CEUs) | | This CME activity is based on transcripts and slides of presentations as delivered by the faculty at the "What's at the Top of the Esophageal Diseases Agenda? Issues to Watch For!" symposium held in Philadelphia, Pennsylvania, on October 16, 2007.
To participate in this activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME/CE Activity- Introduction: The Next Chapter in Gastroesophageal RefluxDavid A. Peura, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- New Ways to Investigate Esophageal Function: pH, Impedance, Manometry, Capsules, and More…Michael F. Vaezi, MD, PhDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Eosinophilic Esophagitis: New Insights Into an Emerging ConcernJoel E. Richter, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Risk Factors for Development of Esophageal Cancer in BE: Implications for ManagementNicholas J. Shaheen, MD, MPHAvailable As: Slides/Audio | Slides/Transcript | Audio
- Supraesophageal Manifestations of GERD: The Extra DimensionRoy K. H. Wong, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Evolving Medical Strategies for GERD: What's at the Forefront?William D. Chey, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
- Questions and AnswersDavid A. Peura, MD, Michael F. Vaezi, MD, PhD, Nicholas J. Shaheen, MD, MPH, Roy K. H. Wong, MD, William D. Chey, MDAvailable As: Slides/Audio | Slides/Transcript | Audio
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 CME Consultants |
|
|
Learning Objectives Upon completion of this activity, participants should be able to: - Evaluate the role of new diagnostic techniques in investigating esophageal function: pH and/or impedance monitoring, high-resolution manometry, wireless Bravo technology,
etc.
- Describe the increasing prevalence of eosinophilic esophagitis in the adult population, its presentation, natural history, and treatment.
- Discuss the changing epidemiology of GERD, Barrett's esophagus, and esophageal adenocarcinoma, and appreciate what interventions might affect natural history and disease progression.
- Evaluate the underlying causes, the diagnosis and subsequent management of the
extraesophageal manifestations of GERD, including persistent cough, asthma, hoarseness, and sleep disturbance.
- Identify the benefits and the challenges of managing the spectrum of acid-related disorders and be familiar with the potential advantages of some of the evolving therapies and their possible role in future management.
Author
Disclosures William D. Chey, MD
Disclosure: Consultant/Advisory Board, Speakers' Bureau, Speaker Honoraria: Axcan, Novartis, Santarus, Salix Smart Pill, Takeda, TAP David A. Peura, MD
Disclosure: Consultant: TAP; Speaker Honoraria: AstraZeneca, Santarus, TAP Joel E. Richter,
MD
Disclosure: Speaker Honoraria: AstraZeneca, TAP Nicholas J. Shaheen, MD, MPH
Disclosure: Grant/Research Support and/or Speaker Honoraria: AstraZeneca, Barrx Medical, Inc, Janssen, Novartis, Procter & Gamble, TAP Michael F. Vaezi, MD, PhD
Disclosure: Grant/Research Support: AstraZeneca, Restech, TAP; Consultant: AstraZeneca,
Restech; Speaker Honoraria: AstraZeneca, TAP Roy K.H. Wong
Disclosure: Speaker Honoraria: AstraZeneca, TAP; Stockholder: Santarus
|
 |
CME Consultants is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Consultants designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit(s) commensurate with the extent of their participation in the activity.
Contact This Provider
|
CME Consultants is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
CME Consultants designates this program for 2.0 contact hours. Participants should claim only those contact hours actually spent in the educational activity. In order to receive credit for this program, each participant must complete the evaluation form and certificate request form. Certificates will be mailed to program participants in approximately six weeks after receipt of the completed evaluation and certification form.
Contact This Provider
|
 CME Consultants is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been designated for 2.0 contact hours (0.200 CEU). There will be no fee for this activity . In order to receive credit, all participants must complete an evaluation, Planned Expiration Date: 1/7/09 ACPE # 309-000-08-004-H04-P.
Contact This Provider
|
|
